Notice of Interim Results

RNS Number : 9619P

Abingdon Health PLC

23 February 2021

 

Notice of Interim Results

York, U.K. 23 February 2021:  Abingdon Health ("Abingdon" or "the Company"), a leading international developer and manufacturer of high quality and effective rapid tests, will announce its maiden Interim Results for the six months ended 31 December 2020 on Tuesday 9 March 2021. 

Chris Yates, Chief Executive Officer, and Melanie Ross, Chief Financial Officer, will host a virtual briefing for sell-side analysts at 11:00 AM on the day of the results. 

For more details or to attend the virtual briefing, please contact [e-mail].

  - Ends-  

Enquiries:

Abingdon Health plc
Chris Yates		Chief Executive Officer		Via Consilium
Melanie Ross		Chief Financial Officer
Chris Hand		Non-Executive Chairman
N+1 Singer		Sole Broker and Nominated Adviser
Shaun Dobson, Peter Steel,				Tel: [phone]
Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Consilium		Financial PR		Tel: [phone]
Matthew Neal		[e-mail]
Mary-Jane Elliott
Lindsey Neville

About Abingdon Health

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx^®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

https://www.abingdonhealth.com/

 

END

 

 

NORFFFVIFLIFFIL